Vera Bradley Foundation for Breast Cancer makes $12.5M commitment to IU School of Medicine

Hemokine modulatory regimen shows promise for TNBC in phase I study

A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase I clinical trial for patients with triple-negative breast cancer, the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.

November 22, 2024

Vol.50 No.44

Drugs & Targets

FDA approves new alternative standard related to mammography report assessments

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”

November 22, 2024

Vol.50 No.44

Clinical

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline

New data indicate that, professional guidelines notwithstanding, doctors rarely address concerns about sexual health when they treat women with cancer.

November 15, 2024

Vol.50 No.43

By Claire Marie Porter

In Brief

NCI renews IU Simon Comprehensive Cancer Center’s designation

NCI renewed the Comprehensive Cancer Center designation to the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, awarding it a five-year, $14.2 million grant.

November 15, 2024

Vol.50 No.43

In Brief

Melissa Fishel named Myles Brand Scholar in Cancer Research at IU Simon

Melissa L. Fishel was named the Myles Brand Scholar in Cancer Research by Indiana University Melvin and Bren Simon Comprehensive Cancer Center. Fishel is a tumor cell biologist working toward new targets and treatments for pancreatic cancer.

November 15, 2024

Vol.50 No.43

Vera Bradley Foundation for Breast Cancer makes $12.5M commitment to IU School of Medicine

YOU MAY BE INTERESTED IN

Hemokine modulatory regimen shows promise for TNBC in phase I study

FDA approves new alternative standard related to mammography report assessments

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline

NCI renews IU Simon Comprehensive Cancer Center’s designation

Melissa Fishel named Myles Brand Scholar in Cancer Research at IU Simon

Renew today!

Subscriber content

Never miss an issue!

Login

Vera Bradley Foundation for Breast Cancer makes $12.5M commitment to IU School of Medicine

YOU MAY BE INTERESTED IN

Hemokine modulatory regimen shows promise for TNBC in phase I study

FDA approves new alternative standard related to mammography report assessments

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancerData indicate low adherence to ASCO guideline

NCI renews IU Simon Comprehensive Cancer Center’s designation

Melissa Fishel named Myles Brand Scholar in Cancer Research at IU Simon

Never miss an issue!

Login

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline